Insmed reported total revenues of $524.4 million for Q3 2026, driven by 29% growth in BRINSUPRI sales and 9% growth in ARIKAYCE compared to prior periods. The company raised its 2026 revenue guidance for BRINSUPRI to $1.35-$1.4 billion and for ARIKAYCE to $460-$470 million, reflecting strong commercial momentum. Key milestones include the launch of BRINSUPRI tablets in Japan and FDA's priority review of ARIKAYCE for expanded use in MAC lung disease. Insmed continues advancing multiple clinical programs and expects significant future growth from its pipeline.
Insmed's third-quarter 2026 report highlights strong revenue growth, with BRINSUPRI sales up 29% and ARIKAYCE sales up 9%, alongside raised full-year revenue guidance. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 17:11 WIB: out of 150 priced US health stocks, 86 rose and 57 fell. Notable movers include Baxter International Inc (BAX) at USD 26.25 (+3.12%), Sana Biotechnology Inc (SANA) at USD 2.71 (+3.04%) with 96% sell order activity, and Gilead Sciences, Inc. (GILD) at USD 163.77 (+2.87%) with 87% buy order activity.
The inaugural SportsTech Breakthrough Awards recognized leading companies and technologies advancing sports technology globally. Winners span categories like athlete performance, wearables, AI analytics, fan engagement, and smart stadium solutions, h...
The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...
AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
